Response rates to avapritinib in the EXPLORER and PATHFINDER studies
| Characteristic . | Phase 1 EXPLORER . | Phase 2 Interim PATHFINDER . |
|---|---|---|
| Response evaluable, n | 53 | 32 |
| AdvSM subtype, n | ||
| ASM | 3 | 2 |
| SM-AHN | 37 | 26 |
| MCL | 13 | 4 |
| ORR by modified IWG criteria, % (CR + CRh + PR + CI) | 75 | 75 |
| Best response, % | ||
| CR | 15 | 0 |
| CRh | 21 | 19 |
| PR | 34 | 31 |
| CI | 6 | 25 |
| SD | 23 | 13 |
| PD | 0 | 3 |
| NE | 2 | 9 |
| ORR by subtype, % | ||
| ASM | 100 | 100 |
| SM-AHN | 76 | 81 |
| MCL | 69 | 25 |
| ORR by any prior therapy, % | ||
| Yes | 69 | 74 |
| No | 86 | 78 |
| ORR by midostaurin history, % | ||
| Prior midostaurin | 59 | 82 |
| Midostaurin naive | 83 | 67 |
| ORR by S/A/R comutation status, % | ||
| Yes | 74 | 71 |
| No | 77 | 80 |
| Characteristic . | Phase 1 EXPLORER . | Phase 2 Interim PATHFINDER . |
|---|---|---|
| Response evaluable, n | 53 | 32 |
| AdvSM subtype, n | ||
| ASM | 3 | 2 |
| SM-AHN | 37 | 26 |
| MCL | 13 | 4 |
| ORR by modified IWG criteria, % (CR + CRh + PR + CI) | 75 | 75 |
| Best response, % | ||
| CR | 15 | 0 |
| CRh | 21 | 19 |
| PR | 34 | 31 |
| CI | 6 | 25 |
| SD | 23 | 13 |
| PD | 0 | 3 |
| NE | 2 | 9 |
| ORR by subtype, % | ||
| ASM | 100 | 100 |
| SM-AHN | 76 | 81 |
| MCL | 69 | 25 |
| ORR by any prior therapy, % | ||
| Yes | 69 | 74 |
| No | 86 | 78 |
| ORR by midostaurin history, % | ||
| Prior midostaurin | 59 | 82 |
| Midostaurin naive | 83 | 67 |
| ORR by S/A/R comutation status, % | ||
| Yes | 74 | 71 |
| No | 77 | 80 |
CI, clinical improvement; CRh, complete remission with partial hematologic recovery; NE, not evaluable; PD, progressive disease; S/A/R, SRSF2, ASXL1, RUNX1; SD, stable disease.